logo-loader
viewCircassia Group PLC

Circassia to hit sales target as cash position improves

Circassia also announced the appointment of Michael Roller as chief financial officer to replace Julien Cotta

Circassia Pharmaceuticals PLC -
Duaklir is a treatment for COPD sufferers

Inhaled drug specialist Circassia PLC’s (LON:CIR) revenues in 2019 were in the middle of its guidance of £60-65mln while cash at the year-end was higher than expected.

Sales in the middle of the range represent an annual increase of about 31% and include a modest contribution from Duaklir, which was launched in the US at the end of October. 

Timing of inventory and rebate payments boosted the cash position to £27mln, but even without these there was a significant improvement in net cash flow in the second half said the AIM-listed group.

Circassia also announced the appointment of Michael Roller as chief financial officer to replace Julien Cotta, who has stepped down after eight years in the role.

Roller previously held the finance director roles at Corin Group and Bioquell, where he worked with Circassia’s executive chairman Ian Johnson.

Quick facts: Circassia Group PLC

Price: 25.55 GBX

LSE:CIR
Market: LSE
Market Cap: £96.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read